Differential expression of exosomal miRNAs between breast cancer patients with and without recurrence

Aiko Sueta¹, Yutaka Yamamoto¹, Mai Tomiguchi¹, Takashi Takeshita¹, Mutsuko Yamamoto-Ibusuki² and Hirotaka Iwase¹

¹Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences, Kumamoto 860-8556, Japan
²Department of Molecular-Targeting Therapy for Breast Cancer, Kumamoto University Hospital, Kumamoto 860-8556, Japan

Correspondence to: Yutaka Yamamoto, email: ys-yama@triton.ocn.ne.jp

Keywords: exosome, microRNA, breast cancer, circulating biomarker, prognostic factor

Received: April 19, 2017 Accepted: June 28, 2017 Published: July 22, 2017

ABSTRACT

Background: Exosomal microRNAs (miRNAs) are promising candidate biomarkers for diagnosis or prognosis for breast cancer. We investigated the prognostic role of exosomal miRNAs in serum samples derived from patients with breast cancer and compared miRNA expression between serum and tumor tissues.

Methods: The miRNA profile derived from exosome between breast cancer patients with recurrence (n = 16) and without recurrence (n = 16) were compared by miRNA PCR array. Further, we examined the expression of miRNAs derived from tissues in the patients with breast cancer with (n = 35) and without recurrence (n = 39) by qRT-PCR.

Results: Of 384 miRNAs, three miRNAs (miR-338-3p, miR-340-5p, and miR-124-3p) were significantly upregulated and eight (miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p, and miR-93-5p) were significantly downregulated in the patients with recurrence. We evaluated the expression of the miRNAs in tumor tissues. The patients with recurrence had higher levels of miR-340 at their primary site as well as in the serum. In contrast, miR-195-5p, miR-17-5p, miR-93-5p, and miR-130a-3p, derived from tumor tissues that were downregulated in the serum from patients with recurrence, were higher in the patients with recurrence than in those with no recurrence. In logistic regression analysis, miR-340-5p, miR-17-5p, miR-130a-3p, and miR-93-5p were significantly associated with recurrence.

Conclusions: Several exosomal miRNAs may be useful biomarkers to predict breast cancer recurrence. We show the different expression patterns of miRNAs between tumor tissues and serum. These findings may suggest selective mechanism of release of exosomal miRNAs by cancer cells to regulate their progression.

INTRODUCTION

In recent years, many new tools in the field of molecular profiling have been developed to accurately predict clinical outcome and response to therapy for early breast cancer [1]. In particular, we attempt to identify circulating cancer-specific biomarkers that are minimally invasive to analyze compared to tissue sampling. Several candidate biomarkers, including DNA, RNA, microRNA (miRNA), proteins and metabolites, have been proposed to date [2].

miRNAs are non-coding small RNA molecules with 19 to 25 nucleotides in length. miRNAs regulate gene expression at the post-transcriptional level by binding to 3’ or 5’ untranslated regions of target messenger RNAs (mRNAs) and leading to inhibition of translation or
regulation of mRNA degradation [3, 4]. Besides their intracellular function, it is demonstrated that they play an important role in transmitting information to modulate their microenvironment. Recent studies indicate that miRNA may serve as oncogenes or tumor suppressor genes. During cancer development, their expression is frequently deregulated in several types of cancer, and abnormal expression levels are associated with cancer clinicopathological features and prognosis. Also in breast cancer, several miRNAs are reported to be valuable biomarkers for detection of cancer or metastases [5, 6]. Among them, miR-10, miR-215, miR-299-5p and miR-41 [7-9] have been suggested to be associated with metastatic breast cancer. In addition to the diagnostic and prognostic values, miRNA expression levels play a role in monitoring treatment response. For example, serum miR-125b is downregulated in HER2-overexpressing breast cancers and may be associated with chemoresistance in patients [10]. Similarly, miR-210 expression was reported to be associated with lower pathological complete response rates in patients who receive trastuzumab therapy [11]. Other putative miRNAs such as miR-200b-3p, miR-190a, and miR-512-5p involved in response to chemotherapy in breast cancer were suggested [12].

miRNAs are commonly incorporated in microvesicles or bound to lipoproteins such as HDL or associated with argonaute-2 (Ago2)-containing complexes in the blood [13]. It has been demonstrated that the majority of miRNAs in body fluids are concentrated in exosomes [14]. On the contrary, Arroyo et al. [13] found that most circulating miRNAs in plasma are cofractionated with Ago2. They also suggested that vesicle-associated versus Ago2 complex-associated miRNAs originate from different cell types.

Exosomes are small membranous vesicles (30–100 nm) including lipid, proteins, miRNAs and mRNAs, and are secreted from viable cells into the blood circulation [15]. They reflect the origin of the secreting cells, and “cargo” in exosomes may be important mediators of intercellular communication [16, 17]. Recently, exosomal miRNAs in body fluids have been used as one of the circulating biomarkers for the detection of several cancers [18-20], based on the findings indicating that cancer patients have elevated levels of tumor-derived exosomes in plasma or serum compared with those in healthy donors. In contrast to growing evidences about comprehensive circulating miRNAs, there is still limited information exclusively regarding exosomal miRNAs which appear to be more reflect to tumor content. Additionally, few reports about exosomal miRNAs evaluate their prognostic value in breast cancer.

In this study, we investigated the prognostic role of the exosomal miRNAs in serum samples derived from patients with primary breast cancer. We performed miRNA array analysis in 32 patients with and without recurrence, identifying several exosomal miRNAs significantly associated with recurrence. Further, we evaluated whether exosomal miRNAs in the serum reflect the origin of the primary tumor by comparing their expression levels between the serum and the tumor.

RESULTS

Comparison of exosomal miRNA profiles between patients with and without recurrence in breast cancer

Patients’ characteristics (n = 32) in the PCR array set are summarized in Table 1. The median follow-up period for patients without recurrence is 100 months. There is no significant difference in clinicopathological factors between patients with and without recurrence. We matched the tumor subgroup for both groups: 56% had tumors of the luminal subtype, 25% had the HER2 subtype, and 19% had the triple negative (TN) subtype. Most patients received adjuvant or neoadjuvant treatment that included endocrine therapy, chemotherapy (anthracycline- and taxan-containing regimen) and trastuzumab therapy.

Analysis of PCR-based arrays for the expression of exosomal miRNAs was performed in serum samples at diagnosis to identify exosomal miRNAs related to recurrence. For all samples, we confirmed that at least 80% of the 384 miRNAs were expressed in the array set. Volcano plot of PCR array data show that 11 miRNAs were significantly expressed in the patients with recurrence (Figure 1).

Of the 384 miRNAs, three were expressed at significantly higher levels and eight were expressed at lower levels in the serum of the patients with recurrence compared with those without recurrence (Table 2); miR-338-3p, miR-340-5p and miR-124-3p were significantly upregulated, and miR-29b-3p, miR-20b-5p, miR-17-5p, miR-130a-3p, miR-18a-5p, miR-195-5p, miR-486-5p and miR-93-5p were significantly downregulated in the patients with recurrence. miR-124-3p had the highest fold change (3.67) among the upregulated genes and miR-93-5p (0.39) among the downregulated genes.

Analysis of miRNA expression in primary breast tumors

Cancer cells appear to secrete exosomal miRNA preferentially into the extracellular space, possibly to alter the cellular environment to favor tumor growth. We also compared the pattern of miRNA expression between the primary breast tumors with and without recurrence. We added more cases to the analysis, selecting 74 patients (35 with recurrence and 39 without recurrence), which included 21 patients used by the PCR array. Patients’ characteristics are shown in Supplementary Table 1. The patients with recurrence were more likely to have larger tumor size (P < 0.01) and advanced stage (P = 0.034), but
Table 1: Patient characteristics in the PCR array set

|                                | Patients with no recurrence (n=16) | Patients with recurrence (n=16) | P     |
|--------------------------------|-----------------------------------|---------------------------------|-------|
| Mean age at diagnosis (min, max)| 54 (30 - 79)                      | 57 (43 - 75)                    | 0.624 |
| Menopausal status              |                                   |                                 |       |
| Premenopausal                  | 6 (38%)                           | 3 (19%)                         |       |
| Postmenopausal                 | 10 (62%)                          | 13 (81%)                        | 0.433 |
| Tumor size (cm)                |                                   |                                 |       |
| Median ± SD                    | 2.6 ± 0.9                         | 2.3 ± 2.1                       | 0.615 |
| Nodal status                   |                                   |                                 |       |
| Negative                       | 8 (50%)                           | 4 (25%)                         |       |
| Positive                       | 8 (50%)                           | 12 (75%)                        | 0.273 |
| Clinical T                     |                                   |                                 |       |
| T1                             | 5 (31%)                           | 5 (31%)                         |       |
| T2                             | 9 (56%)                           | 8 (50%)                         |       |
| T3                             | 2 (13%)                           | 0 (0%)                          |       |
| T4                             | 0 (0%)                            | 3 (19%)                         | 0.168 |
| Stage                          |                                   |                                 |       |
| 1                              | 1 (6%)                            | 4 (25%)                         |       |
| 2                              | 13 (81%)                          | 9 (56%)                         |       |
| 3                              | 2 (13%)                           | 3 (19%)                         | 0.256 |
| Nuclear grade                  |                                   |                                 |       |
| 1,2                            | 9 (56%)                           | 10 (63%)                        |       |
| 3                              | 7 (44%)                           | 6 (38%)                         | 1.000 |
| Ki67 labeling index, median ± SD| 49 ± 21.3                         | 36 ± 26.2                       | 0.396 |
| ER status                      |                                   |                                 |       |
| Negative                       | 6 (38%)                           | 7 (44%)                         |       |
| Positive (≥1%)                 | 10 (62%)                          | 9 (56%)                         | 1.000 |
| PR status                      |                                   |                                 |       |
| Negative                       | 8 (50%)                           | 8 (50%)                         |       |
| Positive (≥1%)                 | 8 (50%)                           | 8 (50%)                         | 1.000 |
| Tumor subtype                  |                                   |                                 |       |
| Luminal (ER and/or PR + and HER2 -) | 9 (56%)                      | 9 (56%)                         |       |
| HER2 (ER and/or PR +/- and HER2 +) | 4 (25%)                        | 4 (25%)                         |       |
| TN (ER and PR and HER2 -)      | 3 (19%)                           | 3 (19%)                         | 1.000 |
| Adjuvant treatment             |                                   |                                 |       |
| Endocrine therapy              | 11 (69%)                          | 9 (56%)                         |       |
| Chemotherapy                   | 7 (44%)                           | 8 (50%)                         |       |
| Trastuzumab                    | 2 (13%)                           | 3 (19%)                         |       |

ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor 2; SD, standard deviation; TN, triple negative.
there was no other difference in clinicopathological factors between the two groups.

Then we compared the expression of miRNAs in the tumors of patients with and without recurrence (Figure 2). Among the upregulated genes by PCR array in the serum, we observed the same tendency only for the miR-340-5p; the patients with recurrence have higher levels of miR-340 at their primary site as well as in the serum (Figure 2A). On the contrary, miR-195-5p, miR-17-5p, miR-93-5p and miR-130a-3p, which were downregulated in the serum of patients with recurrence, were higher in tumors of patients with recurrence compared with those without recurrence (Figure 2B). Regarding the remaining miRNAs, we found no statistical difference between the two groups. In addition, there were no significant correlations in miRNA expression between exosomes and breast tumors by Spearman’s correlation analysis (Supplementary Table 2). In univariate analysis, tumor size, miR-340-5p, miR-17-5p, miR-130a-3p and miR-93-5p were significantly associated with breast cancer recurrence (for each \(P < 0.05\)), and only miR-93-5p was also significant in multivariate analysis (\(P < 0.05\)) (Table 3).

**DISCUSSION**

A number of studies have shown that exosomal miRNAs derived from cancer cells are secreted into the circulation. Exosome-encapsulated miRNAs may represent ideal biomarkers for disease detection at an early stage. In the present study, we investigated the prognostic value of such exosome-derived miRNAs and demonstrated that 11 exosomal miRNAs at diagnosis were associated with breast cancer recurrence. Moreover, we show the different expression pattern of miRNAs between the tumor tissue and serum; miRNAs that were downregulated in the serum of patients with recurrence were highly expressed.

![Figure 1: Volcano plot of PCR-based array between the patients with and without breast cancer recurrence.](image_url)

The red circle indicates a fold change with values greater than 2, and green circles indicate a fold change with values lower than -2.
in the primary tumor compared with patients without recurrence. This finding is not fully consistent with the literature, but may suggest selective mechanism of release of exosomal miRNAs by cancer cells to regulate cancer progression.

Table 2: Differentially expressed miRNAs related to breast cancer recurrence by PCR array

| Mature ID       | Fold change | P    |
|-----------------|-------------|------|
| **Upregulation**|             |      |
| has-miR-338-3p  | 1.62        | 0.019|
| has-miR-340-5p  | 1.77        | 0.046|
| has-miR-124-3p  | 3.67        | <0.01|
| **Downregulation**|           |      |
| has-miR-29b-3p  | 0.69        | 0.049|
| has-miR-20b-5p  | 0.68        | 0.023|
| has-miR-17-5p   | 0.65        | 0.021|
| has-miR-130a-3p | 0.55        | 0.023|
| has-miR-18a-5p  | 0.53        | <0.01|
| has-miR-195-5p  | 0.52        | <0.01|
| has-miR-486-5p  | 0.49        | 0.017|
| has-miR-93-5p   | 0.39        | <0.01|

Figure 2: Comparison of miRNA levels between tumor tissues from patients with recurrence and without recurrence. (A) The miRNA upregulated in the exosomes by PCR array; (B) the miRNAs downregulated in exosomes by PCR array.
Previous studies have mainly focused on miRNA signature based on their expressions in tissue specimens. In breast cancer, miRNAs have been demonstrated to be aberrantly expressed compared to normal breast tissues [21]. A number of miRNAs in breast tumors were identified as useful diagnostic and prognostic biomarkers [22] and have shown to relate to various properties of cancer cells, such as proliferation [23], differentiation, angiogenesis [24], migration [25, 26], cancer stemness [27, 28] and epithelial to mesenchymal transition [29, 30].

There has also been great interest in circulating miRNAs as noninvasive biomarkers for cancer detection or progression. To date, the role of exosomal miRNAs as diagnostic and prognostic markers has been reported in ovarian [31], prostate [19], colon cancer [20] and melanoma [32]. In contrast, studies reporting the identification of exosomal miRNAs in breast cancer are limited, and most of them used breast cancer cell lines [33]. One recent study by Hannafon et al. [21] examined exosomal miRNAs using clinical samples and reported that the expression of plasma exosomal miR-1246 and miR-21 were significantly higher in the group of patients with breast cancer compared with the healthy population. Another report by Eichelser et al. [34] compared blood serum levels of circulating cell-free and exosomal miRNAs and revealed that exosomal miR-101 and miR-373 were significantly different between patients with breast cancer and benign tumors.

Our comprehensive analysis of gene expression showed that 11 miRNAs were significantly aberrantly expressed in the group with recurrence (Table 2). These miRNAs, except for miR-17-5p, miR-20b-5p, miR-93-5p and miR-18a-5p, are considered to be tumor suppressors in various types of cancer according to the literature [35-42]. Some have the evidence on the biological function within cancer cells, but others have no or controversial results; the biological roles of miR-338-3p, miR-29b-3p, miR-486-5p, and miR-130a-3p has not been clarified yet in breast cancer. Identification of novel miRNAs may become a key step in the future development of exosome biomarkers for breast cancer.

Moreover, we compared miRNA expressions between exosomes and tumor tissues at diagnosis. Some studies reported that the miRNA content of the originating cancer cells is similar to that found in circulating exosomes [31]. In the present study, however, miRNA expression in exosomes did not mirror that in the originating tumor tissues (Figure 2 and Supplementary Table 2). Among the miRNAs expressed in primary tumor tissues, miR-340-5p, miR-17-5p, miR-130a-3p and miR-93-5p derived from breast cancer patients with recurrence were highly expressed compared with those from patients without recurrence. However, those miRNAs, except for miR-340-5p, were downregulated in the exosomes of patients with recurrence. miR-17-5p belongs to the miR-17-92 cluster, which is involved in tumor proliferation by controlling the PI3K/Akt/mTOR pathway [43]. Jin et al. showed that miR-17-5p was overexpressed in TN breast cancer (TNBC) and could inhibit ribosomal translation of tumor suppressor genes [44]. Other reports have also shown that miR-93-5p was upregulated in cervical carcinoma or the expression levels of miR-93-5p in TNBC tissues is significantly higher than in non-TNBC tissues [37]. Regarding miR-340-5p, the patients with recurrence

### Table 3: Logistic regression analyses for recurrence by miRNA expression in tissues

| miRNA (high vs. low) | Univariate | Multivariate |
|----------------------|------------|-------------|
| has-miR-338-3p       | 1.97 (0.72–5.42) | 0.189 | |
| has-miR-340-5p       | 4.13 (1.38–12.4)  | 0.011 | 2.58 (0.69–9.66) | 0.159 |
| has-miR-124-3p       | 0.88 (0.31–2.47)  | 0.810 | |
| has-miR-29b-3p       | 1.78 (0.62–5.10)  | 0.286 | |
| has-miR-20b-5p       | 2.70 (0.93–7.85)  | 0.068 | |
| has-miR-17-5p        | 3.25 (1.07–9.84)  | 0.037 | 1.61 (0.41–6.36) | 0.500 |
| has-miR-130a-3p      | 3.25 (1.07–9.84)  | 0.037 | 1.76 (0.46–6.69) | 0.409 |
| has-miR-18a-5p       | 1.69 (0.65–4.38)  | 0.282 | |
| has-miR-195-5p       | 2.70 (0.93–7.85)  | 0.068 | |
| has-miR-486-5p       | 1.16 (0.42–3.24)  | 0.777 | |
| has-miR-93-5p        | 6.56 (1.91–22.5)  | 0.003 | 5.58 (1.46–21.3) | 0.012 |

OR, odds ratio; CI, confidence interval.

aOR was adjusted for tumor size, miR-340-5p, miR-17-5p, miR-130a-3p, and miR-93-5p.
had higher levels of miR-340 at their primary site as well as in the serum. Several studies have suggested the role of miR-340 as a tumor suppressor gene [45, 46], but one report demonstrated the association between miR-340 and chemoresistance [47]. Raychaudhuri et al. reported that the patients with high expression of miR-340 in pretherapeutic biopsies in breast cancer were less likely to achieve pathological complete response (pCR). MiR-340 is predicted to regulate several genes which are associated with tumor growth and proliferation including Jun- and Fos oncogene, and Cyclin Dependent Kinase 5 [47].

A few reports have demonstrated the mechanism of secretion of miRNAs, and secretory miRNAs seem to play a pivotal role as signaling molecules in cancer. However, the mechanisms controlling the secretion of miRNAs into exosomes or the retention of miRNAs inside tumor cells still remain unknown. Pu et al. [48] investigated tissue-specific and plasma miRNA profiles in non-small cell lung cancer and found that the expression levels of specific miRNAs were different between tissues and plasma. Similarly, Matamala et al. [49] have compared miRNA expression levels in breast cancer patients and healthy individuals, leading to the identification of five differentially expressed miRNAs in the plasma. However, some of the miRNAs analyzed were deregulated in opposite directions compared with tumors. According to previous studies, tumors themselves release miRNAs into the circulation [50]. There may be some difference in miRNA profiles within the cancer tissue, which require to grow at the primary site, and those in the exosomes released in the serum, which modulate the extracellular environment. Moreover, exosomes in serum can originate from not only cancer cells but also from nonmalignant cells such as circulating blood cells, although this implication is considered to be substantially low. It is, therefore, possible that the alteration in miRNA expression seen in serum reflects the comprehensive feature of systemic response, displaying difference in exosomal and tissue miRNA profiles.

Our research has several advantages on the study of exosomal miRNAs. Measuring of miRNAs using serum exosomes is ideal in terms of miRNA integrity. Encapsulation by exosomes can protect miRNAs in extreme conditions in the serum, thus maintaining miRNA quality. In our study, we used ExoQuick reagent for exosome isolation while the commonly used methods to isolate exosome is ultracentrifugation. We showed successful isolation of exosomes and miRNA analysis. Compared to ultracentrifugation, commercially available kits like ExoQuick are less time consuming and need lower volume of patient serum [2].

In contrast, several limitations exist in our study. First, there is no reliable endogenous gene for normalization of exosomal miRNAs. We selected miR-16-5p, miR-423-3p and miR-191-5p as reference genes, because they were constantly expressed through our data and were recommended as reference miRNAs in the literature [34, 51]. Second, the stability of exosome in stored patient sample for long term period is unclear. However, Kalra et al. [52] assessed the stability of exosome in plasma and showed that exosome stored at -80 °C were highly stable compared to other storage conditions. We also stored serum sample at -80 °C, but need further research to assure the stability of exosome or miRNAs. Third, the technology functions by ExoQuick cannot avoid mixing of non-exosomal contents with similar size such as apoptotic debris and blood borne cell-derived exosomes. This may cause the difference in the miRNA expression pattern between exosomes and tumor tissues. Finally, we combined all tumor subtypes in our study because we didn’t have many samples available. However, the prognostic significance of each miRNA may differ among tumor subtype. We should perform stratified analyses by tumor subtype to increase the performance for prediction of recurrence in breast cancer.

In conclusion, here we show that 11 exosomal miRNAs are associated with breast cancer recurrence and may be potential candidate biomarkers for breast cancer prognosis. In contrast to growing evidence of the clinical use of circulating miRNAs as diagnostic tools, there is limited data regarding their prognostic impact. Accordingly, we provide additional evidence on it. Interestingly, we report also different miRNA expression patterns between tumors and exosomes, which can be used as prognostic factors. Further clinical and functional studies focusing on these identified miRNAs are needed to validate our findings.

**MATERIALS AND METHODS**

**Study population**

We selected the patients with primary breast cancer with recurrence (n = 16) and without recurrence (n = 16) for analysis of miRNA PCR array. All patients received surgery and treatment at Kumamoto University Hospital between 2003 and 2011 and were diagnosed with invasive breast carcinoma. We matched the tumor subtype for both group as mentioned in the Results section. Tumor subtypes were defined according to the expression of ER, PR and HER2. ER and PR were considered positive if more than 1% of nuclei were stained. HER2 expression was determined by IHC staining based on the Hercep test. Ki67 was scored as the percentage of nuclear-stained cells out of all cancer cells in the hot spot of the tumor, regardless of the intensity in a ×400 high-power field (Ki67 labeling index).

Neoadjuvant or adjuvant treatment was assigned to each patient according to their risk on the basis of clinical parameters, and in accordance with the recommendation of the St. Gallen International Expert Consensus on primary therapy of early breast cancer at the time. All serum samples (500 μL) were collected from breast cancer patients before surgery and treatment.
For analysis of tumor miRNAs, we selected additional breast cancer patients with (n = 35) and without recurrence (n = 39), including 21 patients used for the PCR array analysis. All tumor tissues were obtained from patients before surgery or treatment.

Written informed consent was obtained from all subjects for the collection and research use of breast tumors. Our complete study was approved by the ethics committee of Kumamoto University Graduate School of Medical Sciences.

Exosome isolation and RNA extraction

We store the serum sample at – 80 °C before use in all patients. Exosomes in serum samples (500 µL) were extracted using ExoQuick (System Biosciences, Palo Alto, CA, USA) according to the manufacturer’s instructions. In brief, we combined the reagent into the serum sample and incubated at 4°C for at least 30 min to precipitate the exosome pellet. The size of exosomes was confirmed using the Nanosight LM10 instrument (Nanosight, Tokyo, Japan, Supplementary Figure 1A) and the exosomal membrane marker (CD63) was confirmed by Western blot analysis (Supplementary Figure 1B). Thereafter, total RNAs that include small RNA fraction from exosome pellet were isolated using SeraMir™ Exosome RNA Amplification Kit (System Biosciences) according to the manufacturer’s instructions. The quality of RNA samples and small RNA fraction was checked via the Agilent 2100 Bioanalyzer (Agilent Technologies, Supplementary Figure 1C). The RNA samples were immediately stored at -80°C until they were used.

Western blotting

The pelleted exosomes extracted using ExoQuick (System Biosciences) were resuspended in phosphate-buffered saline following the protein analysis. The proteins were loaded on Mini-PROTEAN® TGX™ gel (Bio-Rad Laboratories, Hercules, CA, USA) and electrophoretically transferred onto Trans-Blot® Turbo™ Mini Nitrocellulose membranes (Bio-Rad Laboratories). The membranes were blocked and incubated overnight at 4°C with the primary antibody anti-CD63 (1:200; Santa Cruz Biotechnology, Fremont, CA, USA). Proteins were visualized with horseradish peroxidase-conjugated secondary antibodies (anti-rabbit IgG, HRP-linked antibody; Cell Signaling Technology, Tokyo, Japan) followed by chemiluminescence detection (Pierce Western Blotting Substrate Plus; Thermo Scientific, Tokyo Japan).

Evaluation of miRNA PCR array in serum

Total RNA (125 ng) extracted from exosomes was reverse transcribed to cDNA using miScript II RT kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s protocol. Then, exosomal miRNA profiling was performed using miRNA PCR array (Qiagen) containing primers for 384 human mature miRNAs according to the manufacturer’s protocol. For the normalization of real-time PCR, we selected miR-16-5p, miR-423-3p and miR-191-5p, because they were constantly expressed in our data and recommended as reference miRNAs in the literatures [34, 51].

Evaluation of miRNA expression in tumor tissues

Total RNA from tissue samples was isolated using the AllPrep® DNA/RNA/miRNA Universal kit (Qiagen) according to the manufacturer’s protocol. RNA was quantified by measuring the A260/A280 absorbance ratios (Nano-Drop Technologies, Wilmington, DE). Total RNA (0.5 µg) was reverse transcribed to cDNA using miScript II RT kit (Qiagen), according to the manufacturer’s protocol. Each real-time quantitative PCR was performed with 0.03 µL of the cDNA, 10×miScript Universal Primer, 10×miScript Primer Assay and 2×QuantiTect SYBR Green PCR Master Kit in the ABI Prism 7500 (Applied Biosystems, Carlsbad, CA). Each reaction (10 µL samples) was performed under the following conditions: initialization for 15 min at 95 °C, and then 40 cycles of amplification, with 15 s at 94°C for denaturation, 30 s at 55°C for annealing, and 30 s at 70°C for elongation. The expression of target genes was normalized against RNU6B and miR-16-5p. The relative expression of each miRNA was calculated using the 2^△△Ct method.

Statistical analysis

In PCR array analysis, candidate miRNAs with differential expression between the patients with and without breast cancer recurrence were determined based on Student’s t-test. Significant miRNAs were defined with p-value < 0.05 and at least 1.5 fold change. The significance of differences in categorized demographic variables was evaluated using Chi-square or Fisher’s exact test and the nonparametric Mann-Whitney U test. The correlation between exosomal and tissue miRNA levels was analyzed using Spearman’s correlation coefficient. Logistic regression methods were adopted for univariate and multivariate analyses to assess the associations of each miRNA with breast cancer recurrence. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. All statistical analyses were carried out using STATA ver.12 (Stata Corp, College Station, TX). All tests were two-sided and p-values < 0.05 were considered statistically significant.

Abbreviations

Ago2: argonaute-2
ER: estrogen receptor
HER2: human epidermal growth factor receptor 2
miRNA: microRNA
mRNA: messenger RNA
OR: odds ratio
PR: progesterone receptor
TN: triple negative

Author contributions

AS participated in the design of the study and performed miRNA analysis and statistical analysis. YY participated in its design and coordination and helped to draft the manuscript. MT, TT, and MYI helped to draft the manuscript. HI conceived of the study, and participated in its design and coordination and helped to draft the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS

The authors are grateful to Y. Azakami for excellent technical support, to M. Suematsu for clinical data management.

CONFLICTS OF INTEREST

The authors have declared no conflicts of interest. No external sources of funding were used for this study.

REFERENCES

1. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012; 490:61-70.
2. Boukouris S, Mathivanan S. Exosomes in bodily fluids are a highly stable resource of disease biomarkers. Proteomics Clin Appl. 2015; 9:358-367.
3. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116:281-297.
4. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6:259-269.
5. Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast Cancer Res. 2013; 15:211.
6. Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012; 195:151-161.
7. van Schooneveld E, Wouters MC, Van der Auwerda I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY, Van Laere SJ. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast Cancer Res. 2012; 14:R34.
8. Chen W, Cai F, Zhang B, Barekati Z, Zhong XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour Biol. 2012; 34:455-462.
9. Zhao FL, Hu GD, Wang XF, Zhang XH, Zhang YK, Yu ZS. Serum overexpression of microRNA-10b in patients with bone metastatic primary breast cancer. J Int Med Res. 2012; 40:859-866.
10. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer. 2006; 5:24.
11. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC Jr, Park ST, Pusztai L, Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012; 118:2603-2614.
12. Casey MC, Sweeney KJ, Brown JA, Kerin MJ. Exploring circulating micro-RNA in the neoadjuvant treatment of breast cancer. Int J Cancer. 2016; 139:12-22.
13. Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agapijan EL, Stirewalt DL, Tait JF, Tewari M. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A. 2011; 108:5003-5008.
14. Gallo A, Tandon M, Alevizos I, Illei GG. The majority of microRNAs detectable in serum and saliva is concentrated in exosomes. PLoS One. 2012; 7:e30679.
15. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol. 2007; 9:654-659.
16. Thery C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2:569-579.
17. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G. The biogenesis and functions of exosomes. Traffic. 2002; 3:321-330.
18. Skog J, Wurdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakfeld XO. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat Cell Biol. 2008; 10:1470-1476.
19. Hessvik NP, Sandvig K, Llorente A. Exosomal miRNAs as biomarkers for prostate cancer. Front Genet. 2013; 4:36.
20. Ogata-Kawata H, Izumiya M, Kurioka D, Homma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, et al. Circulating exosomal microRNAs as biomarkers of colon cancer. PLoS One. 2014; 9:e92921.
21. Hannafon BN, Trigoso YD, Calloway CL, Zhao YD, Lum DH, Welm AL, Zhao ZJ, Blick KE, Dooley WC, Ding WQ. Plasma exosome microRNAs are indicative of breast cancer. Breast Cancer Res. 2016; 18:90.
22. Bertoli G, Cava C, Castiglioni I. MicroRNAs: new biomarkers for diagnosis, prognosis, therapy prediction
and therapeutic tools for breast cancer. Theranostics. 2015; 5:1122-1143.
23. Hong BS, Cho JH, Kim H, Choi EJ, Rho S, Kim J, Kim JH, Choi DS, Kim YK, Hwang D, Gho YS. Colorectal cancer cell-derived microvesicles are enriched in cycle cell-related miRNAs that promote proliferation of endothelial cells. BMC Genomics. 2009; 10:556.
24. Kosaka N, Iguchi H, Hagiwara K, Yoshioka Y, Takeshita F, Ochiya T. Neutral sphingomyelinase 2 (nSMase2)-dependent exosomal transfer of angiogenic microRNAs regulate cancer cell metastasis. J Biol Chem. 2013; 288:10849-10859.
25. Dong G, Liang X, Wang D, Gao H, Wang L, Liu J, Du Z. High expression of miR-21 in triple-negative breast cancers was correlated with a poor prognosis and promoted tumor cell in vitro proliferation. Med Oncol. 2014; 31:57.
26. Min W, Wang B, Li J, Han J, Zhao Y, Su W, Dai Z, Wang X, Ma Q. The expression and significance of five types of miRNAs in breast cancer. Med Sci Monit Basic Res. 2014; 20:97-104.
27. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol. 2013; 139:223-229.
28. Chhabra R, Saini N. MicroRNAs in cancer stem cells: current status and future directions. Tumour Biol. 2014; 35:8395-8405.
29. Wellner U, Schubert J, Burk UC, Schmalhofer O, Zhu F, Sonntag A, Waldvogel B, Vannier C, Darling D, zur Hausen A, Brunton VG, Morton J, Sansom O, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009; 11:1487-1495.
30. Sun X, Jiao X, Pestell TG, Fan C, Qin S, Mirabelli E, Ren H, Pestell RG. MicroRNAs and cancer stem cells: the sword and the shield. Oncogene. 2014; 33:4967-4977.
31. Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008; 110:13-21.
32. Xiao D, Ohlendorf J, Chen Y, Taylor DD, Rai SN, Waigel S, Zacharias W, Hao H, McMasters KM. Identifying mRNA, microRNA and protein profiles of melanoma exosomes. PLoS One. 2012; 7:e46874.
33. Sato-Kuwabara Y, Melo SA, Soares FA, Calin GA. The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review). Int J Oncol. 2015; 46:17-27.
34. Eichelser C, Stuckrath I, Muller V, Milde-Langosch K, Wikman H, Pantel K, Schwarzenbach H. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget. 2014; 5:9650-9663. doi: 10.18632/oncotarget.2520.
35. Chen X, Shi K, Wang Y, Song M, Zhou W, Tu H, Lin Z. Clinical value of integrated-signature miRNAs in colorectal cancer: miRNA expression profiling analysis and experimental validation. Oncotarget. 2015; 6:37544-37556. doi: 10.18632/oncotarget.6065.
36. McDermott AM, Miller N, Wall D, Martyn LM, Ball G, Sweeney KJ, Kerin MJ. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. PLoS One. 2014; 9:e87032.
37. Hu J, Xu J, Wu Y, Chen Q, Zheng W, Lu X, Zhou C, Jiao D. Identification of microRNA-93 as a functional dysregulated miRNA in triple-negative breast cancer. Tumour Biol. 2015; 36:251-258.
38. Guo J, Meng R, Yin Z, Li P, Zhou R, Zhang S, Dong X, Liu L, Wu G. A serum microRNA signature as a prognostic factor for patients with advanced NSCLC and its association with tissue microRNA expression profiles. Mol Med Rep. 2016; 13:4643-4653.
39. Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, Mannoor K, Deepak J, Donahue JM, et al. Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 2014; 33:1181-1189.
40. Zhang Y, Zhang D, Wang F, Xu D, Guo Y, Cui W. Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497) as novel non-invasive biomarkers for detection of cervical cancer. Sci Rep. 2015; 5:17942.
41. Liu L, Ye JX, Qin YZ, Chen QH, Ge LY. Evaluation of miR-29c, miR-124, miR-135a and miR-148a in predicting lymph node metastasis and tumor stage of gastric cancer. Int J Clin Exp Med. 2015; 8:22227-22236.
42. Fiore D, Donnarumma E, Roscigno G, Iaboni M, Russo V, Affinito A, Adamo A, De Martino F, Quintavalle C, Romano G, Greco A, Soini Y, Brunetti A, et al. miR-340 predicts glioblastoma survival and modulates key cancer hallmarks through down-regulation of NRAS. Oncotarget. 2016; 7:19531-19547. doi: 10.18632/oncotarget.6969.
43. Jin L, Lim M, Zhao S, Sano Y, Simone BA, Savage JE, Wickstrom E, Camphausen K, Pestell RG, Simone NL. The metastatic potential of triple-negative breast cancer is decreased via caloric restriction-mediated reduction of the miR-17~92 cluster. Breast Cancer Res Treat. 2014; 146:41-50.
44. Jin YY, Andrade J, Wickstrom E. Non-specific blocking of miR-17-5p guide strand in triple negative breast cancer cells by amplifying passenger strand activity. PLoS One. 2015; 10:e0142574.
45. Mohammadi-Yeganeh S, Paryan M, Arefian E, Vasei M, Ghanbarian H, Mahdian R, Karimipoor M, Soleimani M. MicroRNA-340 inhibits the migration, invasion, and metastasis of breast cancer cells by targeting Wnt pathway. Tumour Biol. 2016; 37:8993-9000.
46. Wu ZS, Wu Q, Wang CQ, Wang XN, Huang J, Zhao JJ, Mao SS, Zhang GH, Xu XC, Zhang N, miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer. 2011; 117:2842-2852.
47. Raychaudhuri M, Bronger H, Buchner T, Kiechle M, Weichert W, Avril S. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2017; 162:511-521.

48. Pu Q, Huang Y, Lu Y, Peng Y, Zhang J, Feng G, Wang C, Liu L, Dai Y. Tissue-specific and plasma microRNA profiles could be promising biomarkers of histological classification and TNM stage in non-small cell lung cancer. Thorac Cancer. 2016; 7:348-354.

49. Matamala N, Vargas MT, Gonzalez-Campora R, Minambres R, Arias JI, Menendez P, Andres-Leon E, Gomez-Lopez G, Yanowsky K, Calvete-Candenas J, Inglada-Perez L, Martinez-Delgado B, Benitez J. Tumor microRNA expression profiling identifies circulating microRNAs for early breast cancer detection. Clin Chem. 2015; 61:1098-1106.

50. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Briant KC, Allen A, Lin DW, Urban N, Drescher CW, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105:10513-10518.

51. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y, Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H. Serum microRNA profiling and breast cancer risk: the use of miR-484/191 as endogenous controls. Carcinogenesis. 2012; 33:828-834.

52. Kalra H, Adda CG, Liem M, Ang CS, Mechler A, Simpson RJ, Hulett MD, Mathivanan S. Comparative proteomics evaluation of plasma exosome isolation techniques and assessment of the stability of exosomes in normal human blood plasma. Proteomics. 2013; 13:3354-3364.